Oncothyreon initiates Phase 1 ONT-380 trial

Oncothyreon (ONTY +2.1%) initiates a Phase 1 trial of a ONT-380/ Herceptin combo in patients with brain metastases from HER2+ breast cancer. ONT-380 is developed in collaboration with Array BioPharma (ARRY +3.6%).

The objective of the trial will be to determine "the maximum-tolerated dose and recommended Phase 2 dose and schedule." (PR)

Relevant drugs in HER2+ breast cancer: GlaxoSmithKline's (GSK +1.6%) Tykerb, Puma Biotechnology's (PBYI +4%) neratinib.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs